我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

抽象的

The Role of Inflammation in Immune-Related Dry Eye Syndrome

Kebina Eliyas

Dry eye syndrome (DES) is a prevalent ocular condition characterized by inadequate tear production or excessive tear evaporation, leading to ocular discomfort and visual disturbances. Immune-related dry eye syndrome (I-DES) is a subtype of DES in which inflammation plays a pivotal role in its pathogenesis. This abstract aims to provide a concise overview of the current understanding of the involvement of inflammation in I-DES.

The immune system plays a critical role in maintaining ocular surface homeostasis and protecting the eye from pathogens. However, in I-DES, an abnormal immune response leads to chronic inflammation, causing damage to the lacrimal glands and ocular surface epithelium. Multiple factors contribute to the initiation and perpetuation of the inflammatory cascade, including environmental triggers, genetic predisposition, and alterations in the microbiome.

Inflammation in I-DES is characterized by the activation of innate and adaptive immune cells, including dendritic cells, T cells, and B cells. Cytokines, chemokines, and inflammatory mediators are released, creating a proinflammatory microenvironment. The disrupted balance between pro-inflammatory and anti-inflammatory factors further exacerbates the condition, leading to a vicious cycle of immune dysregulation.

Studies have identified several key inflammatory pathways involved in I-DES, such as the NF-κB pathway and the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway. Targeting these pathways has shown promising results in preclinical models, and various immunomodulatory therapies are being investigated for their potential to treat I-DES effectively.

In conclusion, inflammation plays a crucial role in the pathogenesis of immune-related dry eye syndrome. Understanding the complex interplay between the immune system and ocular surface is vital for the development of targeted therapies that can alleviate symptoms, improve tear production, and restore ocular surface homeostasis in patients suffering from I-DES. Further research and clinical trials are necessary to fully unravel the mechanisms underlying inflammation in I-DES and develop more effective and personalized treatment strategies.